MiNK Therapeutics clinical trials
Formerly part of Agenus Inc., Jul 17, 2025 · source ↗
The registry lists 4 studies whose lead sponsor is MiNK Therapeutics. 1 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jun 26, 2026.
Before and after it left Agenus Inc.
- First submitted before MiNK Therapeutics left Agenus Inc.
- 3
- First submitted after MiNK Therapeutics left Agenus Inc.
- 1
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- MiNK Therapeutics4 studies
Something wrong with this grouping? Tell us on the Agenus Inc. page.
Studies
Recruiting first, then most recently updated. Showing 4 of 4. All Agenus Inc. studies →
- A Clinical Trial to Evaluate agenT-797 Plus Standard of Care in Participants With Severe Pneumonia With Moderate to Severe Acute Hypoxemic Respiratory FailureRecruitingNCT07615010Phase 2
Sponsor listed in the registry: MiNK Therapeutics · First submitted after MiNK Therapeutics left Agenus Inc.
- A Clinical Trial to Evaluate the Safety of agenT-797 in COVID-19 Participants With ARDSCompletedNCT04582201Phase 1
Sponsor listed in the registry: MiNK Therapeutics · First submitted before MiNK Therapeutics left Agenus Inc.
- A Study Investigating agenT-797 in Participants With Relapsed/Refractory Solid TumorsCompletedNCT05108623Phase 1
Sponsor listed in the registry: MiNK Therapeutics · First submitted before MiNK Therapeutics left Agenus Inc.
- agenT-797 in Participants With Relapsed/Refractory Multiple MyelomaCompletedNCT04754100Phase 1
Sponsor listed in the registry: MiNK Therapeutics · First submitted before MiNK Therapeutics left Agenus Inc.